Position in DTIL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,286,190
+$1,991,185 QoQ
Shares Held
415,671
+486.2% QoQ
Ownership
1.51%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2021
10 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in DTIL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $3,014,740,742 across 267 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
543,897 | $270,169,956 | |
| 2 | INCY |
Incyte Corp
|
1,310,154 | $148,519,056 | |
| 3 | RPRX |
Royalty Pharma plc
|
2,450,669 | $137,409,009 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
991,693 | $88,042,503 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
259,799 | $78,207,292 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
1,333,207 | $75,739,488 | |
| 7 | MANE |
Veradermics, Inc
|
585,560 | $71,988,746 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
1,298,946 | $61,102,419 |
All Filings in DTIL
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,286,190 | 415,671 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $295,005 | 70,915 | Shares | Other | 2026-02-13 | |
| 2024-09-30 | $112,134 | 12,515 | Shares | Other | 2024-11-14 | |
| 2023-09-30 | $140,696 | 412,601 | Shares | Other | 2023-11-14 | |
| 2023-06-30 | $341,345 | 648,945 | Shares | Other | 2023-08-14 | |
| 2023-03-31 | $768,692 | 1,019,486 | Shares | Other | 2023-05-15 | |
| 2022-12-31 | $1,212,243 | 1,018,692 | Shares | Other | 2023-02-14 | |
| 2022-09-30 | $3,096,918 | 2,382,245 | Shares | Other | 2022-11-14 | |
| 2022-06-30 | $3,969,452 | 2,480,908 | Shares | Other | 2022-08-15 | |
| 2021-09-30 | $2,078,688 | 180,129 | Shares | Sole | 2021-11-15 | |
| No filing history on record for this holder in this stock. | ||||||